Last reviewed · How we verify
epinastine HCL and olopatadine HCL
epinastine HCL and olopatadine HCL is a Small molecule drug developed by Hom, Milton M., OD, FAAO. It is currently FDA-approved.
Epinastine HCl and olopatadine HCl are marketed antihistamine drugs with a key composition patent expiring in 2028. The primary competitive advantage lies in their established presence in the market, supported by the patent protection until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | epinastine HCL and olopatadine HCL |
|---|---|
| Sponsor | Hom, Milton M., OD, FAAO |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis (PHASE3)
- Comparison of CL Wear Between Two Allergy Drops (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- epinastine HCL and olopatadine HCL CI brief — competitive landscape report
- epinastine HCL and olopatadine HCL updates RSS · CI watch RSS
- Hom, Milton M., OD, FAAO portfolio CI